

Which patients might be candidates to refer for lecanemab (Leqembi) evaluation?



Proposed eligibility criteria:

- thorough work-up, including MRI, to look for treatable causes of cognitive impairment
- documented diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's dementia. Not appropriate for moderate-severe Alzheimer's. Criteria include:
 - deficits in memory, behavior, language, and/or executive functioning
 - formal cognitive testing (MMSE \geq 22, MOCA \geq 15)
- elevated brain amyloid levels, measured by baseline PET scan or CSF testing via lumbar puncture
- stable cholinesterase inhibitor or memantine dose, if taking
- presence of a caregiver or family member who can ensure the patient receives the drug, including:
 - intravenous infusions every 2 weeks throughout course of therapy
 - periodic MRIs for monitoring cerebral edema, effusions, or hemorrhage
- understanding of the potential modest benefit balanced against the patient's willingness and capacity for testing, treatment, and financial burden

Patients are not good candidates for lecanemab if they have:

- another cause of cognitive impairment
- history of seizures or stroke/TIAs (transient ischemic attacks) in the past 12 months
- delirium or major psychiatric disease (including untreated severe depression)
- anticoagulant use
- an unstable medical condition
- genetic testing revealing the presence of the *APOE ϵ 4* genotype (especially homozygotes)
- immunologic disease requiring immunoglobulins, monoclonal antibodies, immunosuppressants, or plasmapheresis
- coagulopathy (e.g., platelets $<$ 50,000, or INR $>$ 1.5)

Visit qrc0.de/CMS_registry for the latest on Medicare coverage of lecanemab

This guidance is based on multiple sources: the inclusion and exclusion criteria used in the main lecanemab clinical trial CLARITY-AD,¹ protocols from health care organizations such as the Veterans Affairs Health System,² the recommendations of a group of Alzheimer's Disease specialists,³ the American Geriatrics Society,⁴ and additional expert opinion. These recommendations may change as new information emerges; the final decision about referral should be made by the treating clinician in light of a given patient's specific clinical situation and the most current evidence.

(1) van Dyck CH, et al. Lecanemab in early Alzheimer's Disease. *NEJM*. 2022;388(1):9-21. (2) VA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN Pharmacist Executives. Lecanemab-irnb (Leqembi): Criteria for use. 2023; https://www.va.gov/formularyadvisor/DOC_PDF/CFU_Lecanemab-irnb_LEQEMBI_CFU.pdf. (3) Cummings J, et al. Lecanemab: Appropriate Use Recommendations. *J Prev Alzheimers Dis*. 2023;10(3):362-377. (4) American Geriatrics Society. Clinical tools. Lecanemab: What clinicians should know. Nov 16, 2023. <https://geriatricscareonline.org/ProductAbstract/Lecanemab-What-Clinicians-Should-Know/PC0018>.



Balanced information for better care

Copyright 2023 by Alosa Health. All rights reserved.



Pharmaceutical Assistance
Contract for the Elderly



This material is provided by Alosa Health, a nonprofit organization which accepts no funding from any pharmaceutical company. It was supported by the PACE Program of the Department of Aging of the Commonwealth of Pennsylvania. Additional support provided by the John A. Hartford Foundation and Aetna.

Dec 2023